Literature DB >> 14649775

Ventilator-associated pneumonia in a multi-hospital system: differences in microbiology by location.

Hilary M Babcock1, Jeanne E Zack, Teresa Garrison, Ellen Trovillion, Marin H Kollef, Victoria J Fraser.   

Abstract

OBJECTIVE: To determine whether there were differences in the microbiologic etiologies of ventilator-associated pneumonia in different clinical settings.
DESIGN: Observational retrospective cohort study of microbiologic etiologies of ventilator-associated pneumonia from 1998 to 2001 in a multi-hospital system. Microbiologic results were compared between hospitals and between different intensive care units (ICUs) within hospitals.
SETTING: Three hospitals--one pediatric teaching hospital, one adult teaching hospital, and one community hospital--in one healthcare system in the midwestern United States. PATIENTS: Patients at the target hospitals who developed ventilator-associated pneumonia and for whom microbiologic data were available.
RESULTS: Seven hundred fifty-three episodes of ventilator-associated pneumonia had culture data available for review. The most common organisms at all hospitals were Staphylococcus aureus (28.4%) and Pseudomonas aeruginosa (25.2%). The pediatric hospital had higher proportions of Escherichia coli (9.5% vs 2.3%; P < .001) and Klebsiella pneumoniae (13% vs 3.1%; P < .001) than did the adult hospitals. In the pediatric hospital, the pediatric ICU had higher P aeruginosa rates than did the neonatal ICU (33.3% vs 17%; P = .01). In the adult hospitals, the surgical ICU had higher Acinetobacter baumannii rates (10.2% vs. 1.7%; P < .001) than did the other ICUs.
CONCLUSIONS: Microbiologic etiologies of ventilator-associated pneumonia vary between and within hospitals. Knowledge of these differences can improve selection of initial antimicrobial regimens, which may decrease mortality.

Entities:  

Mesh:

Year:  2003        PMID: 14649775     DOI: 10.1086/502149

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  15 in total

1.  KatG and KatE confer Acinetobacter resistance to hydrogen peroxide but sensitize bacteria to killing by phagocytic respiratory burst.

Authors:  Daqing Sun; Sara A Crowell; Christian M Harding; P Malaka De Silva; Alistair Harrison; Dinesh M Fernando; Kevin M Mason; Estevan Santana; Peter C Loewen; Ayush Kumar; Yusen Liu
Journal:  Life Sci       Date:  2016-02-06       Impact factor: 5.037

2.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

Review 3.  Pseudomonas aeruginosa, Candida albicans, and device-related nosocomial infections: implications, trends, and potential approaches for control.

Authors:  George E Pierce
Journal:  J Ind Microbiol Biotechnol       Date:  2005-05-03       Impact factor: 3.346

4.  Effects of intratracheal administration of novispirin G10 on a rat model of mucoid Pseudomonas aeruginosa lung infection.

Authors:  Zhijun Song; Hong Wu; Per Mygind; Dora Raventos; Carsten Sonksen; Hans-Henrik Kristensen; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 5.  Nosocomial infections and multidrug-resistant bacterial organisms in the pediatric intensive care unit.

Authors:  Eric J McGrath; Basim I Asmar
Journal:  Indian J Pediatr       Date:  2010-10-09       Impact factor: 1.967

6.  Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis.

Authors:  Yan Li; Xizhong Cui; Xuemei Li; Steven B Solomon; Robert L Danner; Steven M Banks; Yvonne Fitz; Djillali Annane; Charles Natanson; Peter Q Eichacker
Journal:  Intensive Care Med       Date:  2007-11-09       Impact factor: 17.440

7.  Restoration of lung surfactant protein D by IL-6 protects against secondary pneumonia following hemorrhagic shock.

Authors:  Stephen Thacker; Ana Moran; Mihalis Lionakis; Mary-Ann A Mastrangelo; Tripti Halder; Maria del Pilar Huby; Yong Wu; David J Tweardy
Journal:  J Infect       Date:  2013-11-27       Impact factor: 6.072

Review 8.  Ventilator-associated pneumonia in neonatal and pediatric intensive care unit patients.

Authors:  Elizabeth Foglia; Mary Dawn Meier; Alexis Elward
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

9.  Activities of tobramycin and polymyxin E against Pseudomonas aeruginosa biofilm-coated medical grade endotracheal tubes.

Authors:  Keiko Tarquinio; Kelsey Confreda; James Shurko; Kerry LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

10.  Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.

Authors:  Coleman Rotstein; Gerald Evans; Abraham Born; Ronald Grossman; R Bruce Light; Sheldon Magder; Barrie McTaggart; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.